|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
25
|
|
pubmed:dateCreated |
2007-8-31
|
|
pubmed:abstractText |
In human epidermal growth factor 2 (HER-2)-positive advanced breast cancer, taxanes or vinorelbine plus trastuzumab are among the most widely applied options in the first-line setting. We evaluated the efficacy and tolerability of capecitabine plus trastuzumab after anthracycline and docetaxel or vinorelbine failure and prior trastuzumab exposure.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Anthracyclines,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Deoxycytidine,
http://linkedlifedata.com/resource/pubmed/chemical/Fluorouracil,
http://linkedlifedata.com/resource/pubmed/chemical/Taxoids,
http://linkedlifedata.com/resource/pubmed/chemical/Vinblastine,
http://linkedlifedata.com/resource/pubmed/chemical/capecitabine,
http://linkedlifedata.com/resource/pubmed/chemical/docetaxel,
http://linkedlifedata.com/resource/pubmed/chemical/trastuzumab,
http://linkedlifedata.com/resource/pubmed/chemical/vinorelbine
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
25
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3853-8
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:17679724-Adult,
pubmed-meshheading:17679724-Aged,
pubmed-meshheading:17679724-Anthracyclines,
pubmed-meshheading:17679724-Antibodies, Monoclonal,
pubmed-meshheading:17679724-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:17679724-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:17679724-Brain Neoplasms,
pubmed-meshheading:17679724-Breast Neoplasms,
pubmed-meshheading:17679724-Deoxycytidine,
pubmed-meshheading:17679724-Diarrhea,
pubmed-meshheading:17679724-Disease Progression,
pubmed-meshheading:17679724-Drug Administration Schedule,
pubmed-meshheading:17679724-Female,
pubmed-meshheading:17679724-Fluorouracil,
pubmed-meshheading:17679724-Hematologic Diseases,
pubmed-meshheading:17679724-Humans,
pubmed-meshheading:17679724-Middle Aged,
pubmed-meshheading:17679724-Prospective Studies,
pubmed-meshheading:17679724-Survival Rate,
pubmed-meshheading:17679724-Taxoids,
pubmed-meshheading:17679724-Treatment Failure,
pubmed-meshheading:17679724-Vinblastine
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer.
|
|
pubmed:affiliation |
First Department of Medicine and Cancer Centre, Clinical Division of Oncology, Medical University of Vienna, Vienna, Austria.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|
